Učitavanje...

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Light-chain (AL) amyloidosis remains incurable despite recent therapeutic advances. Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed this phase 2 trial of lenalidomide, cyclophosphamide, and dexamethasone in AL amyloidosis. Thirty-five patients, including 2...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kumar, Shaji K., Hayman, Suzanne R., Buadi, Francis K., Roy, Vivek, Lacy, Martha Q., Gertz, Morie A., Allred, Jacob, Laumann, Kristina M., Bergsagel, Leif P., Dingli, David, Mikhael, Joseph R., Reeder, Craig B., Stewart, A. Keith, Zeldenrust, Steven R., Greipp, Philip R., Lust, John A., Fonseca, Rafael, Russell, Stephen J., Rajkumar, S. Vincent, Dispenzieri, Angela
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2012
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3418771/
https://ncbi.nlm.nih.gov/pubmed/22504925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-407791
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!